Moderna stock more than doubles after melanoma vaccine trial shows "landmark moment"
Updated on: August 19, 2026 / 7:33 PM EDT / CBS News
TL;DR
- Moderna's stock price more than doubled.
- The surge followed positive results from a melanoma vaccine trial.
- The trial's success was referred to as a "landmark moment."